Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.22.2.2
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating expenses:        
Research and development $ (4,353) $ (1,845) $ (11,777) $ (7,010)
General and administrative (2,681) (3,029) (10,680) (10,698)
Total operating expenses (7,034) (4,874) (22,457) (17,708)
Operating loss (7,034) (4,874) (22,457) (17,708)
Interest expense, net (636) (849) (2,441) (4,781)
Adjustments to fair value of derivatives (4,834) 9,783 2,498 (64,526)
Cancellation of share options (17,350)   (17,350)  
Other income, net 175 33 606 167
Total other income / (expense), net (22,645) 8,967 (16,687) (69,140)
(Loss ) / income before income taxes (29,679) 4,093 (39,144) (86,848)
Income tax benefit / (expense) 570 (352) (200) (534)
Net (loss) / income and comprehensive (loss) / income (29,109) 3,741 (39,344) (87,382)
Net (loss) / income attributable to ordinary shareholders $ (29,109) $ 3,741 $ (39,344) $ (87,382)
Net (loss)/ income per share attributable to ordinary shareholders - basic $ (2.38) $ 0.31 $ (3.22) $ (8.40)
Net (loss) /income per share attributable to ordinary shareholders - diluted $ (2.38) $ 0.28 $ (3.22) $ (8.40)
Weighted average ordinary shares outstanding-basic 12,233,374 12,182,002 12,217,188 10,403,889
Weighted average ordinary shares outstanding-diluted 12,233,374 13,483,807 12,217,188 10,403,889